Drugs for Non-Small Cell Lung Cancer Market
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Radiofrequency Ablation (RFA)
1.2.3 Radiation Therapy
1.2.4 Chemotherapy
1.2.5 Targeted Therapies
1.2.6 Immunotherapy
1.3 Market by Application
1.3.1 Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Non-Small Cell Lung Cancer Market Perspective (2017-2028)
2.2 Drugs for Non-Small Cell Lung Cancer Growth Trends by Region
2.2.1 Drugs for Non-Small Cell Lung Cancer Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Drugs for Non-Small Cell Lung Cancer Historic Market Size by Region (2017-2022)
2.2.3 Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2023-2028)
2.3 Drugs for Non-Small Cell Lung Cancer Market Dynamics
2.3.1 Drugs for Non-Small Cell Lung Cancer Industry Trends
2.3.2 Drugs for Non-Small Cell Lung Cancer Market Drivers
2.3.3 Drugs for Non-Small Cell Lung Cancer Market Challenges
2.3.4 Drugs for Non-Small Cell Lung Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue
3.1.1 Global Top Drugs for Non-Small Cell Lung Cancer Players by Revenue (2017-2022)
3.1.2 Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Players (2017-2022)
3.2 Global Drugs for Non-Small Cell Lung Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Non-Small Cell Lung Cancer Revenue
3.4 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio
3.4.1 Global Drugs for Non-Small Cell Lung Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Non-Small Cell Lung Cancer Revenue in 2021
3.5 Drugs for Non-Small Cell Lung Cancer Key Players Head office and Area Served
3.6 Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
3.7 Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Type
4.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Type (2017-2022)
4.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2023-2028)
5 Drugs for Non-Small Cell Lung Cancer Breakdown Data by Application
5.1 Global Drugs for Non-Small Cell Lung Cancer Historic Market Size by Application (2017-2022)
5.2 Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
6.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type
6.2.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
6.2.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
6.2.3 North America Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
6.3 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application
6.3.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
6.3.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
6.3.3 North America Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
6.4 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country
6.4.1 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
6.4.2 North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
7.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type
7.2.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
7.2.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
7.2.3 Europe Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
7.3 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application
7.3.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
7.3.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
7.3.3 Europe Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
7.4 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country
7.4.1 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
7.4.2 Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
8.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type
8.2.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
8.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application
8.3.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
8.4 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region
8.4.1 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
9.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type
9.2.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
9.2.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
9.2.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
9.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application
9.3.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
9.3.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
9.3.3 Latin America Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
9.4 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country
9.4.1 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
9.4.2 Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size (2017-2028)
10.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type
10.2.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Type (2017-2028)
10.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application
10.3.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Share by Application (2017-2028)
10.4 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country
10.4.1 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Bristol-Myers Squibb
11.1.1 Bristol-Myers Squibb Company Details
11.1.2 Bristol-Myers Squibb Business Overview
11.1.3 Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Introduction
11.1.4 Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.1.5 Bristol-Myers Squibb Recent Developments
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Details
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Introduction
11.2.4 GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.2.5 GlaxoSmithKline Recent Developments
11.3 Menarini
11.3.1 Menarini Company Details
11.3.2 Menarini Business Overview
11.3.3 Menarini Drugs for Non-Small Cell Lung Cancer Introduction
11.3.4 Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.3.5 Menarini Recent Developments
11.4 Sanofi
11.4.1 Sanofi Company Details
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Drugs for Non-Small Cell Lung Cancer Introduction
11.4.4 Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.4.5 Sanofi Recent Developments
11.5 Ziopharm Oncology
11.5.1 Ziopharm Oncology Company Details
11.5.2 Ziopharm Oncology Business Overview
11.5.3 Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Introduction
11.5.4 Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.5.5 Ziopharm Oncology Recent Developments
11.6 Alchemia
11.6.1 Alchemia Company Details
11.6.2 Alchemia Business Overview
11.6.3 Alchemia Drugs for Non-Small Cell Lung Cancer Introduction
11.6.4 Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.6.5 Alchemia Recent Developments
11.7 Amgen
11.7.1 Amgen Company Details
11.7.2 Amgen Business Overview
11.7.3 Amgen Drugs for Non-Small Cell Lung Cancer Introduction
11.7.4 Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.7.5 Amgen Recent Developments
11.8 Apotex
11.8.1 Apotex Company Details
11.8.2 Apotex Business Overview
11.8.3 Apotex Drugs for Non-Small Cell Lung Cancer Introduction
11.8.4 Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.8.5 Apotex Recent Developments
11.9 BioMarin Pharmaceutical
11.9.1 BioMarin Pharmaceutical Company Details
11.9.2 BioMarin Pharmaceutical Business Overview
11.9.3 BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Introduction
11.9.4 BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.9.5 BioMarin Pharmaceutical Recent Developments
11.10 CellAct Pharma
11.10.1 CellAct Pharma Company Details
11.10.2 CellAct Pharma Business Overview
11.10.3 CellAct Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.10.4 CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.10.5 CellAct Pharma Recent Developments
11.11 Cerulean Pharma
11.11.1 Cerulean Pharma Company Details
11.11.2 Cerulean Pharma Business Overview
11.11.3 Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Introduction
11.11.4 Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.11.5 Cerulean Pharma Recent Developments
11.12 Cipla
11.12.1 Cipla Company Details
11.12.2 Cipla Business Overview
11.12.3 Cipla Drugs for Non-Small Cell Lung Cancer Introduction
11.12.4 Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.12.5 Cipla Recent Developments
11.13 Cornerstone Pharmaceuticals
11.13.1 Cornerstone Pharmaceuticals Company Details
11.13.2 Cornerstone Pharmaceuticals Business Overview
11.13.3 Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.13.4 Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.13.5 Cornerstone Pharmaceuticals Recent Developments
11.14 Curis
11.14.1 Curis Company Details
11.14.2 Curis Business Overview
11.14.3 Curis Drugs for Non-Small Cell Lung Cancer Introduction
11.14.4 Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.14.5 Curis Recent Developments
11.15 CytRx
11.15.1 CytRx Company Details
11.15.2 CytRx Business Overview
11.15.3 CytRx Drugs for Non-Small Cell Lung Cancer Introduction
11.15.4 CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.15.5 CytRx Recent Developments
11.16 Eli Lilly
11.16.1 Eli Lilly Company Details
11.16.2 Eli Lilly Business Overview
11.16.3 Eli Lilly Drugs for Non-Small Cell Lung Cancer Introduction
11.16.4 Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.16.5 Eli Lilly Recent Developments
11.17 Exelixis
11.17.1 Exelixis Company Details
11.17.2 Exelixis Business Overview
11.17.3 Exelixis Drugs for Non-Small Cell Lung Cancer Introduction
11.17.4 Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.17.5 Exelixis Recent Developments
11.18 Fresenius Kabi
11.18.1 Fresenius Kabi Company Details
11.18.2 Fresenius Kabi Business Overview
11.18.3 Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Introduction
11.18.4 Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.18.5 Fresenius Kabi Recent Developments
11.19 Genentech
11.19.1 Genentech Company Details
11.19.2 Genentech Business Overview
11.19.3 Genentech Drugs for Non-Small Cell Lung Cancer Introduction
11.19.4 Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.19.5 Genentech Recent Developments
11.20 Hikma Pharmaceuticals
11.20.1 Hikma Pharmaceuticals Company Details
11.20.2 Hikma Pharmaceuticals Business Overview
11.20.3 Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.20.4 Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.20.5 Hikma Pharmaceuticals Recent Developments
11.21 Hospira
11.21.1 Hospira Company Details
11.21.2 Hospira Business Overview
11.21.3 Hospira Drugs for Non-Small Cell Lung Cancer Introduction
11.21.4 Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.21.5 Hospira Recent Developments
11.22 Intas Pharmaceuticals
11.22.1 Intas Pharmaceuticals Company Details
11.22.2 Intas Pharmaceuticals Business Overview
11.22.3 Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.22.4 Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.22.5 Intas Pharmaceuticals Recent Developments
11.23 Karyopharm Therapeutics
11.23.1 Karyopharm Therapeutics Company Details
11.23.2 Karyopharm Therapeutics Business Overview
11.23.3 Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Introduction
11.23.4 Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.23.5 Karyopharm Therapeutics Recent Developments
11.24 Kyowa Hakko Kirin
11.24.1 Kyowa Hakko Kirin Company Details
11.24.2 Kyowa Hakko Kirin Business Overview
11.24.3 Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Introduction
11.24.4 Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.24.5 Kyowa Hakko Kirin Recent Developments
11.25 Ligand Pharmaceuticals
11.25.1 Ligand Pharmaceuticals Company Details
11.25.2 Ligand Pharmaceuticals Business Overview
11.25.3 Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Introduction
11.25.4 Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
11.25.5 Ligand Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Radiofrequency Ablation (RFA)
Table 3. Key Players of Radiation Therapy
Table 4. Key Players of Chemotherapy
Table 5. Key Players of Targeted Therapies
Table 6. Key Players of Immunotherapy
Table 7. Global Drugs for Non-Small Cell Lung Cancer Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 8. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2022) & (US$ Million)
Table 10. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2017-2022)
Table 11. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 12. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region (2023-2028)
Table 13. Drugs for Non-Small Cell Lung Cancer Market Trends
Table 14. Drugs for Non-Small Cell Lung Cancer Market Drivers
Table 15. Drugs for Non-Small Cell Lung Cancer Market Challenges
Table 16. Drugs for Non-Small Cell Lung Cancer Market Restraints
Table 17. Global Drugs for Non-Small Cell Lung Cancer Revenue by Players (2017-2022) & (US$ Million)
Table 18. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Players (2017-2022)
Table 19. Global Top Drugs for Non-Small Cell Lung Cancer by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2021)
Table 20. Ranking of Global Top Drugs for Non-Small Cell Lung Cancer Companies by Revenue (US$ Million) in 2021
Table 21. Global 5 Largest Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue (CR5 and HHI) & (2017-2022)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Non-Small Cell Lung Cancer Product Solution and Service
Table 24. Date of Enter into Drugs for Non-Small Cell Lung Cancer Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 27. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2017-2022)
Table 28. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 29. Global Drugs for Non-Small Cell Lung Cancer Revenue Market Share by Type (2023-2028)
Table 30. Global Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 31. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Application (2017-2022)
Table 32. Global Drugs for Non-Small Cell Lung Cancer Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 33. Global Drugs for Non-Small Cell Lung Cancer Revenue Share by Application (2023-2028)
Table 34. North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 35. North America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028) & (US$ Million)
Table 36. North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 37. North America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028) & (US$ Million)
Table 38. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 39. North America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 40. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 41. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028) & (US$ Million)
Table 42. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 43. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028) & (US$ Million)
Table 44. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 45. Europe Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 46. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 47. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028) & (US$ Million)
Table 48. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 49. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028) & (US$ Million)
Table 50. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2017-2022) & (US$ Million)
Table 51. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size by Region (2023-2028) & (US$ Million)
Table 52. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 53. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028) & (US$ Million)
Table 54. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 55. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028) & (US$ Million)
Table 56. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 57. Latin America Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 58. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2017-2022) & (US$ Million)
Table 59. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Type (2023-2028) & (US$ Million)
Table 60. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2017-2022) & (US$ Million)
Table 61. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Application (2023-2028) & (US$ Million)
Table 62. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2017-2022) & (US$ Million)
Table 63. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size by Country (2023-2028) & (US$ Million)
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Drugs for Non-Small Cell Lung Cancer Product
Table 67. Bristol-Myers Squibb Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Developments
Table 69. GlaxoSmithKline Company Details
Table 70. GlaxoSmithKline Business Overview
Table 71. GlaxoSmithKline Drugs for Non-Small Cell Lung Cancer Product
Table 72. GlaxoSmithKline Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 73. GlaxoSmithKline Recent Developments
Table 74. Menarini Company Details
Table 75. Menarini Business Overview
Table 76. Menarini Drugs for Non-Small Cell Lung Cancer Product
Table 77. Menarini Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 78. Menarini Recent Developments
Table 79. Sanofi Company Details
Table 80. Sanofi Business Overview
Table 81. Sanofi Drugs for Non-Small Cell Lung Cancer Product
Table 82. Sanofi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 83. Sanofi Recent Developments
Table 84. Ziopharm Oncology Company Details
Table 85. Ziopharm Oncology Business Overview
Table 86. Ziopharm Oncology Drugs for Non-Small Cell Lung Cancer Product
Table 87. Ziopharm Oncology Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 88. Ziopharm Oncology Recent Developments
Table 89. Alchemia Company Details
Table 90. Alchemia Business Overview
Table 91. Alchemia Drugs for Non-Small Cell Lung Cancer Product
Table 92. Alchemia Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 93. Alchemia Recent Developments
Table 94. Amgen Company Details
Table 95. Amgen Business Overview
Table 96. Amgen Drugs for Non-Small Cell Lung Cancer Product
Table 97. Amgen Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 98. Amgen Recent Developments
Table 99. Apotex Company Details
Table 100. Apotex Business Overview
Table 101. Apotex Drugs for Non-Small Cell Lung Cancer Product
Table 102. Apotex Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 103. Apotex Recent Developments
Table 104. BioMarin Pharmaceutical Company Details
Table 105. BioMarin Pharmaceutical Business Overview
Table 106. BioMarin Pharmaceutical Drugs for Non-Small Cell Lung Cancer Product
Table 107. BioMarin Pharmaceutical Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 108. BioMarin Pharmaceutical Recent Developments
Table 109. CellAct Pharma Company Details
Table 110. CellAct Pharma Business Overview
Table 111. CellAct Pharma Drugs for Non-Small Cell Lung Cancer Product
Table 112. CellAct Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 113. CellAct Pharma Recent Developments
Table 114. Cerulean Pharma Company Details
Table 115. Cerulean Pharma Business Overview
Table 116. Cerulean Pharma Drugs for Non-Small Cell Lung Cancer Product
Table 117. Cerulean Pharma Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 118. Cerulean Pharma Recent Developments
Table 119. Cipla Company Details
Table 120. Cipla Business Overview
Table 121. Cipla Drugs for Non-Small Cell Lung Cancer Product
Table 122. Cipla Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 123. Cipla Recent Developments
Table 124. Cornerstone Pharmaceuticals Company Details
Table 125. Cornerstone Pharmaceuticals Business Overview
Table 126. Cornerstone Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 127. Cornerstone Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 128. Cornerstone Pharmaceuticals Recent Developments
Table 129. Curis Company Details
Table 130. Curis Business Overview
Table 131. Curis Drugs for Non-Small Cell Lung Cancer Product
Table 132. Curis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 133. Curis Recent Developments
Table 134. CytRx Company Details
Table 135. CytRx Business Overview
Table 136. CytRx Drugs for Non-Small Cell Lung Cancer Product
Table 137. CytRx Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 138. CytRx Recent Developments
Table 139. Eli Lilly Company Details
Table 140. Eli Lilly Business Overview
Table 141. Eli Lilly Drugs for Non-Small Cell Lung Cancer Product
Table 142. Eli Lilly Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 143. Eli Lilly Recent Developments
Table 144. Exelixis Company Details
Table 145. Exelixis Business Overview
Table 146. Exelixis Drugs for Non-Small Cell Lung Cancer Product
Table 147. Exelixis Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 148. Exelixis Recent Developments
Table 149. Fresenius Kabi Company Details
Table 150. Fresenius Kabi Business Overview
Table 151. Fresenius Kabi Drugs for Non-Small Cell Lung Cancer Product
Table 152. Fresenius Kabi Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 153. Fresenius Kabi Recent Developments
Table 154. Genentech Company Details
Table 155. Genentech Business Overview
Table 156. Genentech Drugs for Non-Small Cell Lung Cancer Product
Table 157. Genentech Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 158. Genentech Recent Developments
Table 159. Hikma Pharmaceuticals Company Details
Table 160. Hikma Pharmaceuticals Business Overview
Table 161. Hikma Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 162. Hikma Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 163. Hikma Pharmaceuticals Recent Developments
Table 164. Hospira Company Details
Table 165. Hospira Business Overview
Table 166. Hospira Drugs for Non-Small Cell Lung Cancer Product
Table 167. Hospira Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 168. Hospira Recent Developments
Table 169. Intas Pharmaceuticals Company Details
Table 170. Intas Pharmaceuticals Business Overview
Table 171. Intas Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 172. Intas Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 173. Intas Pharmaceuticals Recent Developments
Table 174. Karyopharm Therapeutics Company Details
Table 175. Karyopharm Therapeutics Business Overview
Table 176. Karyopharm Therapeutics Drugs for Non-Small Cell Lung Cancer Product
Table 177. Karyopharm Therapeutics Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 178. Karyopharm Therapeutics Recent Developments
Table 179. Kyowa Hakko Kirin Company Details
Table 180. Kyowa Hakko Kirin Business Overview
Table 181. Kyowa Hakko Kirin Drugs for Non-Small Cell Lung Cancer Product
Table 182. Kyowa Hakko Kirin Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 183. Kyowa Hakko Kirin Recent Developments
Table 184. Ligand Pharmaceuticals Company Details
Table 185. Ligand Pharmaceuticals Business Overview
Table 186. Ligand Pharmaceuticals Drugs for Non-Small Cell Lung Cancer Product
Table 187. Ligand Pharmaceuticals Revenue in Drugs for Non-Small Cell Lung Cancer Business (2017-2022) & (US$ Million)
Table 188. Ligand Pharmaceuticals Recent Developments
Table 189. Research Programs/Design for This Report
Table 190. Key Data Information from Secondary Sources
Table 191. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Non-Small Cell Lung Cancer Market Share by Type: 2021 VS 2028
Figure 2. Radiofrequency Ablation (RFA) Features
Figure 3. Radiation Therapy Features
Figure 4. Chemotherapy Features
Figure 5. Targeted Therapies Features
Figure 6. Immunotherapy Features
Figure 7. Global Drugs for Non-Small Cell Lung Cancer Market Share by Application: 2021 VS 2028
Figure 8. Hospitals Case Studies
Figure 9. Clinics Case Studies
Figure 10. Other Case Studies
Figure 11. Drugs for Non-Small Cell Lung Cancer Report Years Considered
Figure 12. Global Drugs for Non-Small Cell Lung Cancer Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Drugs for Non-Small Cell Lung Cancer Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Drugs for Non-Small Cell Lung Cancer Market Share by Region: 2021 VS 2028
Figure 15. Global Drugs for Non-Small Cell Lung Cancer Market Share by Players in 2021
Figure 16. Global Top Drugs for Non-Small Cell Lung Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Non-Small Cell Lung Cancer as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Drugs for Non-Small Cell Lung Cancer Revenue in 2021
Figure 18. North America Drugs for Non-Small Cell Lung Cancer Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2017-2028)
Figure 20. North America Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2017-2028)
Figure 21. North America Drugs for Non-Small Cell Lung Cancer Market Size Share by Country (2017-2028)
Figure 22. United States Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Drugs for Non-Small Cell Lung Cancer Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2017-2028)
Figure 26. Europe Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2017-2028)
Figure 27. Europe Drugs for Non-Small Cell Lung Cancer Market Size Share by Country (2017-2028)
Figure 28. Germany Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Drugs for Non-Small Cell Lung Cancer Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2017-2028)
Figure 36. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Drugs for Non-Small Cell Lung Cancer Market Size Share by Region (2017-2028)
Figure 38. China Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
List of Figures
Figure 44. Latin America Drugs for Non-Small Cell Lung Cancer Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2017-2028)
Figure 46. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Drugs for Non-Small Cell Lung Cancer Market Size Share by Country (2017-2028)
Figure 48. Mexico Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Drugs for Non-Small Cell Lung Cancer Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Type (2017-2028)
Figure 52. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Drugs for Non-Small Cell Lung Cancer Market Size Share by Country (2017-2028)
Figure 54. Turkey Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Drugs for Non-Small Cell Lung Cancer Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 58. GlaxoSmithKline Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 59. Menarini Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 60. Sanofi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 61. Ziopharm Oncology Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 62. Alchemia Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 63. Amgen Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 64. Apotex Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 65. BioMarin Pharmaceutical Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 66. CellAct Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 67. Cerulean Pharma Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 68. Cipla Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 69. Cornerstone Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 70. Curis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 71. CytRx Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 72. Eli Lilly Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 73. Exelixis Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 74. Fresenius Kabi Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 75. Genentech Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 76. Hikma Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 77. Hospira Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 78. Intas Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 79. Karyopharm Therapeutics Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 80. Kyowa Hakko Kirin Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 81. Ligand Pharmaceuticals Revenue Growth Rate in Drugs for Non-Small Cell Lung Cancer Business (2017-2022)
Figure 82. Bottom-up and Top-down Approaches for This Report
Figure 83. Data Triangulation
Figure 84. Key Executives Interviewed
Industry Market Size
